Comparative Study Between Two Models of a Non-invasive Glucose Monitoring Device

Type1diabetes Clinical Trial

Official title:

Comparative Study Between Two Models of a Non-invasive Glucose Monitoring Device

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03530644
• Other study ID #: RSP-14
• Status: Completed
• Phase: N/A
• Start date: August 28, 2018
• Est. completion date: December 14, 2018

Study information

• Verified date: December 2018
• Source: RSP Systems A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical study has been launched to compare the performances of two models of a non-invasive glucose monitoring device.

Description:

Subjects will be optical screened at baseline visit. Study comprises two in-clinic visits. Subjects will arrive in a fasting state and and oral glucose bolus will be administered.

Subjects will during each of two study days be subjected to optical readings on two different device prototypes. During each of the study days, FGM readings, capillary blood samples and arterialized venous blood samples will be collected.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3
• Est. completion date: December 14, 2018
• Est. primary completion date: December 14, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male and female subjects 18 years of age or older

• Diabetic type 1 patients

• Insulin pump users

• Skin phototype 1-4

Exclusion Criteria:

• For female participants: Pregnancy or subject is attempting to conceive or not willing and able to practice birth control during the study duration

• For female participants: Breastfeeding

• Subjects not able to understand and read Danish

• In Investigator's opinion, subject is not able to follow instructions as specified in the protocol

• Rejection by optical screenings

• Subjects not able to hold hand/arm steadily (including tremors and Parkinson's Disease)

• Diagnosed with reduced circulation

• Extensive skin changes, tattoos or diseases on probe application site

• Known allergy to medical grade alcohol

• Known allergy to adhesives

• Systemic or topical administration of glucocorticoids for the past 7 days

• Subjects undergoing dialysis treatment

• Medical history or any condition that may, in the opinion of the Investigator, compromise the subject's ability to participate

• Concomitant medical condition which could present a risk to the safety or welfare of the subject or study staff

• Subjects currently enrolled in another study

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type1diabetes

Intervention

Device:
• WM3.4NR
The investigational medical device will collect spectral Raman data from tissue.
• P0.1
The investigational medical device will collect spectral Raman data from tissue.

Locations

Country	Name	City	State
Denmark	Steno Diabetes Center Odense	Odense

Sponsors (1)

Lead Sponsor	Collaborator
RSP Systems A/S

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Generation and validation of prediction models	Two in-clinic visits each of a duration of 7-8 hours are scheduled for each subject. Subjects will enter clinic in fasting state and will receive an oral glucose bolus. Glucose excursion is followed with frequent capillary and venous blood samples along with FGM readings. In parallel, optical glucose data from two different prototypes of the investigational medical device will be collected.; Optical glucose readings will be masked to the subjects.; Collected data will be used to generate individual calibration models capable of predicting tissue glucose. Models from the two devices will be validated on independent data sets using MARD, ISUP and Consensus Error Grid endpoint measures.	4 months
Primary	Performance evaluation	Validated calibration models will be compared with MARD, ISUP and Consensus Error Grid endpoint measures.	4 months
Secondary	Safety by paucity of adverse events	To evaluate safety of devices in a descriptive manner by the paucity of adverse events. Adverse events will be recorded during study.	4 months